Research programme: anti-infectives - Merck/Schering-Plough

Drug Profile

Research programme: anti-infectives - Merck/Schering-Plough

Alternative Names: Anti-infectives research programme - Merck/Schering-Plough

Latest Information Update: 08 Feb 2017

Price : $50

At a glance

  • Originator Cubist Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 01 Nov 2000 TerraGen Discovery has been acquired by Cubist Pharmaceuticals
  • 11 Jun 1999 Preclinical development for Bacterial infections in Canada (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top